FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387503477> ?p ?o ?g. }

• W4387503477 abstract "Cholangiocarcinoma (CCA) is an aggressive and diverse malignancy with a poor prognosis. Related to a typical indolent course of progression, most cases of CCA are metastatic or locally advanced at the time of presentation. For patients with nonresectable tumors or metastatic disease, the mainstay of treatment is comprehensive with combination chemotherapy. The first-line chemotherapeutic combination for the treatment of CCA are cisplatin and gemcitabine-based chemotherapies. However, many locally advanced and progressive CCA cases are refractory to first-line management. Within the past few years, the increase in the incidence of metastatic CCA and its poor prognosis has brought to light the need for novel therapeutic approaches to treatment. With advancements in next-generation genome sequencing, multiple molecular pathways have been identified in the pathogenesis of CCA and have shown great potential as alternative treatments in cases of CCA refractory to surgical resection. FGFR2 fusions or rearrangements have been identified in 10-16% of all intrahepatic CCA and are thought to serve as a pathway of resistance for a number of nonresectable and refractory cases of cholangiocarcinoma. A novel therapeutic agent that has been discussed is infigratinib, a selective, ATP-competitive inhibitor of fibroblast growth factor receptor 2 (FGFR2). In a phase 1 trial, infigratinib showed a safe profile and showed remarkable clinical efficacy in advanced CCA with FGFR2 fusions or rearrangements in phase II trials. As of May 2021, the Food and Drug Administration (FDA) approved infigratinib for CCA largely based on tumor response and duration of response. As of 2021, infigratinib, futibatinib, and pemigatinib, similar novel selective FGFR inhibitors, have been approved by the FDA for the treatment of locally advanced or metastatic CCA harboring FGFR2 gene mutations. The present investigation reviews the development of infigratinib in particular and its clinical efficacy compared to other available treatment options for cholangiocarcinoma. While the side effect profile of infigratinib is minimal, particularly GI side effects, when compared with futibatinib and pemigatinib, the overall response rate (ORR) and median overall survival (mOS) for infigratinib (ORR=23.1%, mOS=3.8 months) was significantly lower than futibatinib (ORR=35.8%, mOS=21.1 months) and pemigatinib (ORR=35.5%, mOS=21.1 months). While there is ample promise for the use of infigratinib as molecular-directed therapy in the treatment of CCA harboring FGFR2 mutations, there is an appropriate concern for patient-acquired resistance. The heterogeneous nature of FGFR mutations and the emergence of different resistance mechanisms emphasize a need for more agents to inhibit FGFR rearrangements effectively." @default.
• W4387503477 created "2023-10-11" @default.
• W4387503477 creator A5000498009 @default.
• W4387503477 creator A5014876140 @default.
• W4387503477 creator A5018558604 @default.
• W4387503477 creator A5019859846 @default.
• W4387503477 creator A5024318488 @default.
• W4387503477 creator A5049463237 @default.
• W4387503477 creator A5054588784 @default.
• W4387503477 creator A5060374510 @default.
• W4387503477 creator A5063319470 @default.
• W4387503477 creator A5074761280 @default.
• W4387503477 creator A5075986774 @default.
• W4387503477 creator A5078230916 @default.
• W4387503477 date "2023-10-10" @default.
• W4387503477 modified "2023-10-12" @default.
• W4387503477 title "Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements" @default.
• W4387503477 cites W1953852747 @default.
• W4387503477 cites W1972977506 @default.
• W4387503477 cites W2032626834 @default.
• W4387503477 cites W2072564984 @default.
• W4387503477 cites W2107977954 @default.
• W4387503477 cites W2115261608 @default.
• W4387503477 cites W2117834374 @default.
• W4387503477 cites W2156687990 @default.
• W4387503477 cites W2291693837 @default.
• W4387503477 cites W2312132282 @default.
• W4387503477 cites W2604648767 @default.
• W4387503477 cites W2751681739 @default.
• W4387503477 cites W2763492611 @default.
• W4387503477 cites W2999431991 @default.
• W4387503477 cites W3010944770 @default.
• W4387503477 cites W3037904585 @default.
• W4387503477 cites W3041239657 @default.
• W4387503477 cites W3082946658 @default.
• W4387503477 cites W3084384393 @default.
• W4387503477 cites W3186228217 @default.
• W4387503477 cites W3192574431 @default.
• W4387503477 cites W3209811467 @default.
• W4387503477 cites W3217577800 @default.
• W4387503477 cites W4205752139 @default.
• W4387503477 cites W4206736819 @default.
• W4387503477 cites W4238000034 @default.
• W4387503477 cites W4285197845 @default.
• W4387503477 cites W4290017213 @default.
• W4387503477 cites W4306771925 @default.
• W4387503477 cites W4311359029 @default.
• W4387503477 cites W4311532817 @default.
• W4387503477 cites W4317355154 @default.
• W4387503477 cites W4322744870 @default.
• W4387503477 cites W4386743363 @default.
• W4387503477 doi "https://doi.org/10.7759/cureus.46792" @default.
• W4387503477 hasPublicationYear "2023" @default.
• W4387503477 type Work @default.
• W4387503477 citedByCount "0" @default.
• W4387503477 crossrefType "journal-article" @default.
• W4387503477 hasAuthorship W4387503477A5000498009 @default.
• W4387503477 hasAuthorship W4387503477A5014876140 @default.
• W4387503477 hasAuthorship W4387503477A5018558604 @default.
• W4387503477 hasAuthorship W4387503477A5019859846 @default.
• W4387503477 hasAuthorship W4387503477A5024318488 @default.
• W4387503477 hasAuthorship W4387503477A5049463237 @default.
• W4387503477 hasAuthorship W4387503477A5054588784 @default.
• W4387503477 hasAuthorship W4387503477A5060374510 @default.
• W4387503477 hasAuthorship W4387503477A5063319470 @default.
• W4387503477 hasAuthorship W4387503477A5074761280 @default.
• W4387503477 hasAuthorship W4387503477A5075986774 @default.
• W4387503477 hasAuthorship W4387503477A5078230916 @default.
• W4387503477 hasBestOaLocation W43875034771 @default.
• W4387503477 hasConcept C121332964 @default.
• W4387503477 hasConcept C126322002 @default.
• W4387503477 hasConcept C142424586 @default.
• W4387503477 hasConcept C143998085 @default.
• W4387503477 hasConcept C2776694085 @default.
• W4387503477 hasConcept C2779399171 @default.
• W4387503477 hasConcept C31760486 @default.
• W4387503477 hasConcept C502942594 @default.
• W4387503477 hasConcept C535046627 @default.
• W4387503477 hasConcept C71924100 @default.
• W4387503477 hasConcept C87355193 @default.
• W4387503477 hasConceptScore W4387503477C121332964 @default.
• W4387503477 hasConceptScore W4387503477C126322002 @default.
• W4387503477 hasConceptScore W4387503477C142424586 @default.
• W4387503477 hasConceptScore W4387503477C143998085 @default.
• W4387503477 hasConceptScore W4387503477C2776694085 @default.
• W4387503477 hasConceptScore W4387503477C2779399171 @default.
• W4387503477 hasConceptScore W4387503477C31760486 @default.
• W4387503477 hasConceptScore W4387503477C502942594 @default.
• W4387503477 hasConceptScore W4387503477C535046627 @default.
• W4387503477 hasConceptScore W4387503477C71924100 @default.
• W4387503477 hasConceptScore W4387503477C87355193 @default.
• W4387503477 hasLocation W43875034771 @default.
• W4387503477 hasOpenAccess W4387503477 @default.
• W4387503477 hasPrimaryLocation W43875034771 @default.
• W4387503477 hasRelatedWork W2377100155 @default.
• W4387503477 hasRelatedWork W2403801615 @default.
• W4387503477 hasRelatedWork W2528167051 @default.
• W4387503477 hasRelatedWork W2793887421 @default.
• W4387503477 hasRelatedWork W2883338879 @default.
• W4387503477 hasRelatedWork W3016698866 @default.

• next